(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...

Ongoing fundamental research on cancer cells could be used to create new drugs and therapies that fight the spread of cancer ...

Here, we used deep full-length single-cell RNA-sequencing to distinguish post-mitotic cone and rod developmental states and cone-specific features that contribute to retinoblastomagenesis. The ...

T helper (TH) cells are essential immune cells that help other immune cells function effectively. When activated in response ...

FT836 Preclinical Data Shows Robust Antigen-mediated Expansion, Functional Persistence, and Durable Anti-tumor Activity in ...

18, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell ...